{"id":"W4403563661","doi":"10.1016/j.ejca.2024.115078","title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Foundation Medicine; Chugai Pharmaceutical; Genentech; MacroGenics; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma; Eisai; Seagen; GlaxoSmithKline; UroGen Pharma; Advanced Accelerator Applications; Pfizer; Incyte; Ipsen; Clovis Oncology; Boston Scientific Corporation; AstraZeneca; Invitae; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Sanofi; Exelixis; Amgen; Myriad Genetics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Internal medicine; Cancer; Urology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003947389,0.0003312698,0.001424988,0.0002961075,0.0001488833,0.0002197221,0.0002559861,0.00001936235,0.0005610866],"category_scores_gemma":[0.0002672162,0.0001657228,0.0004632451,0.0005570817,0.0002207302,0.0002558813,0.00005505905,0.0007253647,0.00001515074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006612433,"about_ca_system_score_gemma":0.001636167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001674884,"about_ca_topic_score_gemma":0.001195294,"domain_scores_codex":[0.9950359,0.001790524,0.001496842,0.0003473671,0.000931884,0.0003974715],"domain_scores_gemma":[0.9977923,0.0009135942,0.000464566,0.0002749509,0.000336482,0.000218076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9179422,0.0006616054,0.0009717153,0.0001049046,0.007482593,0.01153473,0.01265477,0.00435532,0.009339742,0.00001999169,0.002279197,0.03265325],"study_design_scores_gemma":[0.9734591,0.001403355,0.002364937,0.001730851,0.004822382,0.00007484552,0.004506913,0.003233227,0.001606529,0.000053998,0.006461192,0.0002826962],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8557346,0.1327611,0.0001725144,0.005362111,0.0007133179,0.003637596,0.0002097132,0.00002978861,0.001379234],"genre_scores_gemma":[0.9866821,0.008910757,0.0001015115,0.0001673531,0.0006420541,0.000193138,0.00001948009,0.00006264145,0.003220927],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1309475,"threshold_uncertainty_score":0.6757981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.055486289193787,"score_gpt":0.4074318813970119,"score_spread":0.3519455922032249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}